A detailed history of Principal Financial Group Inc transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 16,524 shares of RNA stock, worth $673,518. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,524
Previous 17,627 6.26%
Holding current value
$673,518
Previous $449,000 50.33%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

SELL
$22.73 - $40.85 $25,071 - $45,057
-1,103 Reduced 6.26%
16,524 $675,000
Q1 2024

Apr 29, 2024

SELL
$9.16 - $25.52 $17,019 - $47,416
-1,858 Reduced 9.54%
17,627 $449,000
Q4 2023

Feb 07, 2024

SELL
$4.87 - $9.37 $7,115 - $13,689
-1,461 Reduced 6.98%
19,485 $176,000
Q3 2023

Nov 02, 2023

BUY
$6.3 - $11.35 $21,690 - $39,078
3,443 Added 19.67%
20,946 $133,000
Q2 2023

Aug 07, 2023

BUY
$10.62 - $17.34 $21,378 - $34,905
2,013 Added 13.0%
17,503 $194,000
Q1 2023

May 09, 2023

BUY
$15.35 - $25.65 $53,111 - $88,749
3,460 Added 28.76%
15,490 $237,000
Q4 2022

Feb 09, 2023

BUY
$10.06 - $22.66 $13,409 - $30,205
1,333 Added 12.46%
12,030 $266,000
Q3 2022

Nov 09, 2022

BUY
$15.46 - $23.43 $165,375 - $250,630
10,697 New
10,697 $175,000
Q4 2021

Feb 09, 2022

SELL
$20.4 - $28.66 $953,373 - $1.34 Million
-46,734 Closed
0 $0
Q3 2021

Nov 09, 2021

SELL
$18.16 - $25.21 $27,203 - $37,764
-1,498 Reduced 3.11%
46,734 $1.15 Million
Q2 2021

Aug 10, 2021

BUY
$19.62 - $29.26 $484,731 - $722,897
24,706 Added 105.02%
48,232 $1.19 Million
Q1 2021

May 10, 2021

BUY
$20.28 - $28.15 $35,652 - $49,487
1,758 Added 8.08%
23,526 $513,000
Q4 2020

Feb 08, 2021

BUY
$24.73 - $35.12 $538,322 - $764,492
21,768 New
21,768 $556,000

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $2.12B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.